文献速递慢性肾脏病肾移植血液净化与透析

儿童肾脏病患者接种3剂BNT162b2的体液与细胞免疫原性

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases.
PubMed 文献 · Kidney Int Rep · 2023-08-28

该研究纳入59例5-18岁慢性肾脏病(CKD)患儿,评估加速3剂BNT162b2基础免疫的免疫原性与安全性。3剂后S-RBD IgG血清阳性率90.5%-93.8%,sVNT几何均值78.6%-79.3%;Omicron BA.1中和能力较野生型明显降低(82.7% vs 27.4%,P<0.0001),但T细胞应答保留。免疫抑制者中和反应较弱,不良反应多为轻中度。

要点

  • 59例CKD患儿加速3剂BNT162b2后S-RBD IgG血清阳性率90.5%-93.8%。
  • Omicron BA.1中和水平82.7% vs 27.4%显著低于野生型(P<0.0001)。
  • 免疫抑制尤其霉酚酸酯治疗者中和反应较弱,T细胞应答保留。

核心结论

  • 加速3剂BNT162b2基础免疫在儿童和青少年肾脏病患者中具有免疫原性和安全性。

研究设计与样本

  • 研究纳入59例慢性肾脏病(CKD)患儿(平均年龄12.9岁;30例男性),涵盖是否使用免疫抑制、透析或肾移植者。
  • 5-11岁接种0.1 ml BNT162b2,11-18岁接种0.3 ml BNT162b2。

主要发现

  • 3剂后S-RBD IgG血清阳性率90.5%-93.8%,sVNT几何均值水平78.6%-79.3%。
  • 免疫抑制者中和反应较弱,尤其接受更多免疫抑制剂或霉酚酸酯治疗者。
  • Omicron BA.1中和水平第3剂后sVNT%为82.7% vs 27.4%(野生型 vs Omicron BA.1,Omicron BA.1较野生型降低,P<0.0001)。
  • 针对Omicron BA.1的T细胞应答保留。
  • 接种后感染患者(接种2剂)Omicron BA.1中和反应高于未感染者,呈现混合免疫。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with severe kidney diseases are at risk of complications from COVID-19; however, little is known about the effectiveness of COVID-19 vaccines in children and adolescents with kidney diseases. METHODS: We investigated the immunogenicity and safety of an accelerated 3-dose primary series of COVID-19 vaccination among 59 pediatric patients with chronic kidney disease (CKD) (mean age 12.9 years; 30 male) with or without immunosuppression, dialysis, or kidney transplant. Dosage was 0.1 ml BNT162b2 to those aged 5 to 11 years, and 0.3 ml BNT162b2 to those aged 11 to 18 years. RESULTS: Three doses of either vaccine type elicited significant antibody responses that included spike receptor-binding domain (S-RBD) IgG (90.5%-93.8% seropositive) and surrogate virus neutralization (geometric mean sVNT% level, 78.6%-79.3%). There were notable T cell responses. Weaker neutralization responses were observed among those on immunosuppression, especially those receiving higher number of immunosuppressants or on mycophenolate mofetil. Neutralization was reduced against Omicron BA.1 compared to wild type (WT, i.e., ancestral) (post-dose 3 sVNT% level; 82.7% vs. 27.4%; P < 0.0001). However, the T cell response against Omicron BA.1 was preserved, which likely confers protection against severe COVID-19. Infected patients exhibited hybrid immunity after vaccination, as evidenced by the higher Omicron BA.1 neutralization response among these infected patients who received 2 doses compared with those who were uninfected. Generally mild or moderate adverse reactions following vaccines were reported. CONCLUSION: An accelerated 3-dose primary series with BNT162b2 is immunogenic and safe in young children and adolescents with kidney diseases.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Leung D, Chan EY, Mu X, et al. Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases. Kidney Int Rep. 2023. PMID: 38025215. doi:10.1016/j.ekir.2023.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。